Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001757898
$232.22
+4.85% · delayed ~15 min
Last price from Oct 22, 2026
$22.71B market value
From STERIS plc's FY2026 10-K, filed May 29, 2026 · read the filing
STERIS makes medical devices and equipment. It took in $5.94B last year, which makes it a mid-sized company. Of every dollar it sells, about 13 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by Sohi Mohsen, not under a pre-arranged plan.
$956.8K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From STERIS plc's FY2026 annual filing · share price scored separately
Largest year-over-year changes in FY2026
Cash
$171.7M → $439.6M
Operating income
$866.6M → $1.10B
Profit
$614.6M → $782.3M
Free cash flow
$778.0M → $972.4M
Measured against FY2025, from the 10-K filed May 29, 2026
Improved: +156.0%
$171.7M to $439.6MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +27.1%
$866.6M to $1.10BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
+27.3%
How the latest move compares (quote delayed ~15 min), and what was published around it
STE rose 4.85% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 3.2 points above its sector and 5.9 points above the market.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 9% a year for the next 10 years. Over the last 9 years it grew by about 16% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $782.3M last year.
Slowly. Sales grew 8.7% last year.
No. At its current cash flow it could clear its debt in about 1.1 years. For every $1 it owes, it owns $3.03 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 31 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 18% of the cash its operations generated. It has paid in each of the last 10 years.
GoodFigures from the FY2026 annual filing
Last year it earned $782.3M and generated $1.34B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202610-K · May 29, 2026Filing for FY2026 | FY202510-K · May 29, 2026Filing for FY2025 | FY202410-K · May 29, 2026Filing for FY2024 | FY202310-K · May 29, 2026Filing for FY2023 | FY202210-K · May 29, 2024Filing for FY2022 | ChangeFY2026 vs FY2025 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B | +8.7% |
| Cost of revenue | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B | +8.3% |
| Gross profit | $2.63B | $2.40B | $2.22B | $1.98B | $1.88B | +9.3% |
| Gross marginGross profit ÷ revenueWhat is this? | 44.2% | 44.0% | 43.2% | 43.7% | 44.6% | +0.2 pts |
| Selling, general and administrative | $1.41B | $1.33B | $1.25B | $1.09B | $1.32B | +5.5% |
| Operating income | $1.10B | $866.6M | $836.1M | $791.1M | $477.8M | +27.1% |
| Operating marginOperating income ÷ revenueWhat is this? | 18.6% | 15.9% | 16.3% | 17.4% | 11.3% | +2.7 pts |
| Interest expense | $60.7M | $86.3M | $144.4M | $108.0M | $89.5M | −29.7% |
| Income before tax | $1.05B | $796.2M | $702.8M | $680.3M | $366.8M | +31.5% |
| Net income | $782.3M | $614.6M | $378.2M | $107.0M | $243.9M | +27.3% |
| Net marginNet income ÷ revenueWhat is this? | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | +1.9 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $8.00 | $6.25 | $3.82 | $1.09 | $2.44 | +27.9% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| STESTERIS plc · this page | 9.0/10 | 9/9 | 8.7% | 13.2% | 29.03x |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 228 shares
Holds 12,956 shares after this filing.
Exercised stock options — 4,058 shares at $86.23 ($349.9K)
Holds 28,363 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Signed a material agreement
Read the filingQuarterly report for Q1 FY2027
Revenue +7.3% · Operating margin +1.5 pts · Cash +72.4% — against Q1 FY2026
Read the filingWrite down why you are following STERIS plc, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 158 subsidiaries named in its 10-K, incorporated across 46 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from STE's 10-K for fiscal year 2026 (period ending 2026-03-31, filed May 29, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2026 | 9.0 | 9/9 | 10-K, filed May 29, 2026 |
| FY2025 | 9.0 | 8/9 | 10-K, filed May 29, 2026 |
| FY2024 | 7.0 | 7/9 | 10-K, filed May 29, 2024 |
| FY2023 | 7.0 | 6/9 | 10-K, filed May 26, 2023 |
| FY2022 | 8.0 | 4/9 | 10-K, filed May 31, 2022 |
| FY2021 | 9.0 | 4/9 | 10-K, filed May 28, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
9 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
5.27
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.68
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
$614.6M to $782.3MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +25.0%
$778.0M to $972.4MSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +27.9%
$6.25 to $8.00Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +8.7%
$5.46B to $5.94BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +9.3%
$2.40B to $2.63BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +2.7 pts
15.9% to 18.6%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +1.9 pts
11.3% to 13.2%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -5.5%
$1.92B to $1.81BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Changed: +10.0%
$219.9M to $241.8MNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Q1 FY2027 against Q1 FY2026, from the 10-Q filed Aug 7, 2026 — read it.
Improved: +72.4%
$279.7M to $482.3MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +16.2%
$246.0M to $285.8MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +7.3%
$1.39B to $1.49BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +8.9%
$628.0M to $684.2MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +12.8%
$177.4M to $200.1MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +1.5 pts
17.7% to 19.1%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: -14.3%
$326.4M to $279.6MNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +14.0%
$1.80 to $2.05Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -13.3%
$1.90B to $1.65BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: -1.0%
98.5M to 97.5MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: +9.3%
$56.2M to $61.4MNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Changed: -6.5%
$93.6M to $87.5MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 6% and 11%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 14 analysts covering this company, as of . Their views, not this site's.
Of 14 analysts publishing on this company, 3 say strong buy, 7 say buy and 4 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 29.8x — investors pay $29.8 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 0.49x |
| MDTMedtronic plc | 8.0/10 | 7/9 | 8.4% | 13.2% | 25.76x | 0.87x |
|---|
| Median of peers | 8.0/10 | — | 8.4% | 13.2% | 25.76x | 0.87x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 4,058 shares at $235.78 ($956.8K)
Holds 24,305 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 4,110 shares ($953.1K) on or after .
Shares originally obtained via Exercise & Hold.
Filed notice to sell 4,058 shares ($956.8K) on or after .
Shares originally obtained via Employee Stock Option Exercise.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Held a shareholder vote
Had a director or senior officer leave or join
Read the filingAnnounced restructuring or exit costs · Published results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2026
Revenue +8.7% · Operating margin +2.7 pts · Cash +156.0% — against FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2026
Revenue +9.2% · Cash +173.0% · Gross profit +7.4% — against Q3 FY2026
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2026
Revenue +9.9% · Operating margin +1.7 pts · Cash +85.4% — against Q2 FY2026
Read the filingPublished results
Read the filingQuarterly report for Q1 FY2026
Revenue +8.7% · Operating margin +3.2 pts · Free cash flow +66.9% — against Q1 FY2026
Read the filingHad a director or senior officer leave or join · Published results · Held a shareholder vote
Read the filingHad a director or senior officer leave or join
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +6.2% · Profit margin +3.9 pts · Profit +62.5% — against FY2024
Read the filingPublished results
Read the filingThe first 40 of 158. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-05-29. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026
Yahoo Finance ·
Reasons to Add STE Stock to Your Portfolio Right Now
Yahoo Finance ·
Steris inks $2.1B Xodus buyout to expand consumables portfolio
Yahoo Finance ·
Steris outlays $2.1bn to acquire Xodus Medical
Yahoo Finance ·
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)
Yahoo Finance ·
STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
Yahoo Finance ·
STERIS (STE) Stock Looks Fully Priced on Current Cash Flow Expectations
Yahoo Finance ·
STERIS Stock: Is STE Underperforming the Healthcare Sector?
Yahoo Finance ·
STERIS Stock Outlook: Is Wall Street Bullish or Bearish?
Yahoo Finance ·
2 S&P 500 Stocks to Own for Decades and 1 We Ignore
Yahoo Finance ·
Sector Update: Healthcare Stocks Rise Late Afternoon
Yahoo Finance ·
3 Healthcare Stocks That Fall Short
Yahoo Finance ·
Primary sources and further research